How much funding has Nucleome Therapeutics raised?

Nucleome Therapeutics has raised $48.2M in total funding, most recently a Series A round.

Who are Nucleome Therapeutics's investors?

Nucleome Therapeutics's investors include M Ventures, Johnson & Johnson Innovation, Pfizer Ventures, British Patient Capital, Oxford Science Enterprises.

When was Nucleome Therapeutics founded?

Nucleome Therapeutics was founded in 2019.

Where is Nucleome Therapeutics headquartered?

Nucleome Therapeutics is headquartered in Oxford, United Kingdom.

What industry is Nucleome Therapeutics in?

Nucleome Therapeutics operates in Artificial Intelligence, Biotech.

How many employees does Nucleome Therapeutics have?

Nucleome Therapeutics has 11-50 employees.

Nucleome Therapeutics

Oxford, United Kingdom · Founded 2019 · $48.2M raised

Artificial Intelligence

Biotech

Headquarters: Oxford
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: nucleome.com
Total Funding: $48.2M
Last Round: $48.2M Series AOct 2022
Rounds: 1

About

Nucleome Therapeutics is an Oxford-based biotechnology company using 3D genomics and machine learning to discover precision medicines for complex diseases. Founded in 2019 by leading experts in gene regulation from the University of Oxford, the company decodes disease-linked non-coding genome variants by mapping the 3D architecture of the genome. Nucleome is backed by Oxford Sciences Innovation and operates from the Oxford BioEscalator. In February 2026 the company appointed Dr. Michelle Morrow as Chief Scientific Officer to advance its pipeline.

Summary

Nucleome Therapeutics is an Artificial Intelligence company based in Oxford, United Kingdom, founded in 2019. It has raised $48.2M in total across 1 round, most recently a $48.2M Series A round in Oct 2022. Investors include M Ventures, Johnson & Johnson Innovation and Pfizer Ventures.